Clinical Trials Logo

Clinical Trial Summary

Patients with marginal physiologic reserve, severe frailty, and/or malnutrition may be regarded as unsuitable candidates for advanced cardiac replacement therapies. However, little data exist on precisely which measures are predictive of subsequent adverse events. Assessment of nutritional status and frailty is still largely predicated on crude and obsolete parameters, such as baseline serum albumin level or body mass index (BMI). In this prospective cohort study the investigators will evaluate the use of bio-electrical impedance spectroscopy (BIS) as a measure of body composition and assess the associations with surgical outcomes.


Clinical Trial Description

This is a prospective cohort study, with study visits at Enrollment and subsequently at ≤10 days , 1 month (+/- 7 days), 3 months (+/- 7 days) , 6 months (+/- 14 days) , and 12 months (+/- 14 days) after heart transplant surgery. BIS measurements will be performed on patients both in the pretransplant and post-transplant periods except when contraindicated in the pretransplant setting concerning patients with advanced heart failure. Because the use of BIS is contraindicated in the setting of permanent pacemaker and/or internal cardiac defibrillator (ICD) devices, BIS assessment cannot be performed in the pretransplant setting for patients with advanced heart failure as the majority of these patients already have these devices in place. However, at the time of cardiac transplantation, these devices will be removed from those patients with advanced heart failure and the BIS measurements will then be performed shortly after transplantation, and then serially during the post-transplant period at various time intervals for one year in order to track changes in body composition. These measurements will be compared to traditional measurements performed at the time of preoperative evaluation by the nutritional and dietitian support team. ;


Study Design


Related Conditions & MeSH terms

  • Heart Transplant Failure and Rejection

NCT number NCT03373279
Study type Observational
Source Baylor Research Institute
Contact
Status Active, not recruiting
Phase
Start date February 1, 2017
Completion date December 30, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT03102125 - Allograft Dysfunction in Heart Transplant Phase 4
Active, not recruiting NCT04380311 - Precision Guided Tacrolimus Dosing in Pediatric Heart Transplant N/A
Completed NCT02109575 - Quantitative Detection of Circulating Donor-Specific DNA in Organ Transplant Recipients (DTRT-Multi-Center Study)
Completed NCT04610320 - Daratumumab-SC for Highly Sensitized Patients Awaiting Heart Transplantation Phase 1
Active, not recruiting NCT03386539 - Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score Phase 3
Not yet recruiting NCT05081739 - Donor-Derived Cell-free DNA to DETect REjection in Cardiac Transplantation N/A
Recruiting NCT03499197 - Heart TIMING - Heart Transplantation IMagING
Recruiting NCT03538509 - Percutaneous Coronary Intervention in Patients witH OrthotoPic hEart Transplantation: the PCI-HOPE a Multicenter Study.
Recruiting NCT03050892 - Impact of Donor and Recipient ST2 / IL-33 Pathway After Heart Transplantation N/A
Recruiting NCT05994274 - A Clinical Study of Association Between Postoperative Dyslipidemia and Organ Rejection in Transplant Patients
Active, not recruiting NCT03575910 - HEARTBiT: Multi-Marker Blood Test for Acute Cardiac Transplant Rejection
Withdrawn NCT04088903 - Study of Daratumumab for Decreasing Circulating Antibodies in Sensitized Patients Awaiting Heart Transplantation Phase 1